These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 15088313

  • 1. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
    J Rheumatol; 2004 Apr; 31(4):808-10. PubMed ID: 15088313
    [Abstract] [Full Text] [Related]

  • 2. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
    Stenbøg EV, Windelborg B, Hørlyck A, Herlin T.
    Scand J Rheumatol; 2006 Apr; 35(4):318-21. PubMed ID: 16882598
    [Abstract] [Full Text] [Related]

  • 3. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS, Durán DG, Peracaula CS, Iznardi CR, Tardío JO.
    An Pediatr (Barc); 2010 Nov; 73(5):268-71. PubMed ID: 20678974
    [Abstract] [Full Text] [Related]

  • 4. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 5. [Kawasaki disease: what you need to know].
    Bajolle F, Laux D.
    Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
    [Abstract] [Full Text] [Related]

  • 6. Angiogenesis, tumor necrosis factor-alpha and procoagulant factors in coronary artery giant aneurysm of a fatal infantile Kawasaki disease.
    Pucci A, Martino S, Celeste A, Linari A, Tibaldi M, Camosso E, Muscio M, Barattia G, Riva C, Bartoloni G.
    Cardiovasc Pathol; 2008 Nov; 17(3):186-9. PubMed ID: 18402791
    [Abstract] [Full Text] [Related]

  • 7. Response of refractory Kawasaki disease to intravenous methylprednisolone.
    Shah I, Prabhu SS.
    Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935
    [Abstract] [Full Text] [Related]

  • 8. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 9. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
    O'connor MJ, Saulsbury FT.
    Clin Pediatr (Phila); 2007 May 17; 46(4):345-8. PubMed ID: 17475994
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr 17; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 11. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC, Aronoff SC.
    Pediatrics; 2005 Oct 17; 116(4):989-95. PubMed ID: 16199713
    [Abstract] [Full Text] [Related]

  • 12. [Kawasaki disease: clinical characteristics and cardiovascular involvement in a cohort of 121 patients].
    Calabri GB, Falcini F, Favilli S, Pollini I, Capuzzo L, Simonini G, De Simone L.
    Pediatr Med Chir; 2002 Oct 17; 24(5):352-7; discussion 397-9. PubMed ID: 12494535
    [Abstract] [Full Text] [Related]

  • 13. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin.
    Shirley DA, Stephens I.
    Pediatr Infect Dis J; 2010 Oct 17; 29(10):978-9. PubMed ID: 20431427
    [Abstract] [Full Text] [Related]

  • 14. [Cardiovascular complications of Kawasaki disease: clinical cases].
    Sica F, d'Amato E, Colapietra T, Romondia A.
    Pediatr Med Chir; 1995 Oct 17; 17(6):531-3. PubMed ID: 8668589
    [Abstract] [Full Text] [Related]

  • 15. Coronary artery aneurysms in Kawasaki disease: the Puerto Rican experience.
    Villavicencio R, Sánchez-Rosetti J.
    P R Health Sci J; 1987 Apr 17; 6(1):7-12. PubMed ID: 3615799
    [Abstract] [Full Text] [Related]

  • 16. [Giant coronary thrombus as a complication of Kawasaki disease].
    Kádár K, Piskóthy A, Bendig L.
    Orv Hetil; 1993 Oct 31; 134(44):2431-3. PubMed ID: 8233462
    [Abstract] [Full Text] [Related]

  • 17. Corticosteroid treatment of refractory Kawasaki disease.
    Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, Ebbeson R, Ramsey SE, Laxer RM, Silverman ED, McCrindle BW, Ratnapalan S, Feldman BM.
    J Rheumatol; 2006 Apr 31; 33(4):803-9. PubMed ID: 16583481
    [Abstract] [Full Text] [Related]

  • 18. Infliximab treatment for refractory Kawasaki syndrome.
    Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME.
    J Pediatr; 2005 May 31; 146(5):662-7. PubMed ID: 15870671
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
    J Pediatr; 2011 Apr 31; 158(4):644-649.e1. PubMed ID: 21129756
    [Abstract] [Full Text] [Related]

  • 20. Giant coronary artery aneurysms in Kawasaki disease: the cost of a missed diagnosis.
    Marta L, Francisco A, Anjos R.
    Cardiol Young; 2013 Aug 31; 23(4):608-9. PubMed ID: 23910022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.